External Links

(Note: CBC does not endorse and is not responsible for the content of external links.)

Reality TV star Kim Kardashian is no stranger to criticism, having spent the better part of the last decade in the public eye. But she's probably never faced negative publicity like this before: The Food and Drug Administration says Kardashian's social media posts violate federal drug-promotion rules.

Kardashian recently began promoting a prescription pill to treat morning sickness through her social media accounts. Such endorsement deals are relatively common for celebrities. In posts to Instagram and Facebook earlier this month Kardashian talks about her struggles with nausea due to pregnancy.

Kim Kardashian recently began promoting a prescription pill that treats morning sickness through her social media accounts.

"I tried changing things about my lifestyle, like my diet, but nothing helped, so I talked to my doctor," the post states. "He prescribed me #Diclegis, and I felt a lot better and most importantly, it's been studied and there was no increased risk to the baby."

The posts link to a company website that includes the FDA-approved labelling information.

Kardashian is five months pregnant with her second child, a boy, with husband Kanye West.

But FDA regulators say the posts violate rules for promoting drugs because they don't mention side-effects of Diclegis, which include sleepiness that can make it dangerous to drive or perform other activities that require mental alertness. The drug label warns that Diclegis should not be combined with alcohol or other medications that cause drowsiness, such as sleeping aids or certain pain relievers.

The FDA posted its warning letter online Tuesday, addressed to the CEO of Quebec-based drugmaker Duchesnay Inc., which markets the drug. The letter notes that the privately held company received a similar warning in 2013 for omitting risk information from a letter to doctors.

FDA regulators are "concerned that Duchesnay is continuing to promote Diclegis in a violative manner," states the letter dated Aug. 7.

The agency calls on the company to remove the social media posts immediately and outline a plan for preventing future violations by Aug. 21

Duchesnay said in a statement it "will take quick action in responding to the FDA's letter and immediately and effectively address any issues." The company is based in Blainville, Quebec.

The FDA approved Diclegis in 2013 to treat vomiting and nausea in pregnant women who do not respond to more traditional measures. It is the only prescription drug approved in the U.S. for morning sickness.

Kim Kardashian's representative, Ina Treciokas, said the social media posts on Twitter and Instagrams were written together with the drug company.

To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.

By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.

Note: The CBC does not necessarily endorse any of the views posted. By submitting your comments, you acknowledge that CBC has the right to reproduce, broadcast and publicize those comments or any part thereof in any manner whatsoever. Please note that comments are moderated and published according to our submission guidelines.